Methyl-CpG-binding protein 2 is phosphorylated by homeodomain-interacting protein kinase 2 and contributes to...

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Mutations in methyl-CpG-binding protein 2 (MeCP2) are linked to Rett syndrome and neurological disorders.
• MeCP2 regulates gene transcription by recruiting co-repressor complexes.
• MeCP2 phosphorylation, particularly at Ser 80, Ser 229, and Ser 421, influences its silencing activity in the brain.

Purpose of the Study:

• To identify the specific kinases responsible for MeCP2 phosphorylation in vivo.
• To investigate the functional consequences of MeCP2 phosphorylation at Ser 80.
• To elucidate the role of the identified kinase in MeCP2-mediated gene regulation and cellular processes.

Main Methods:

• Co-immunoprecipitation assays to detect protein-protein interactions.
• In vitro kinase assays to confirm phosphorylation.
• In vivo studies using mouse models to assess phosphorylation and functional effects.
• Analysis of apoptosis induction and cell proliferation.

Main Results:

• Homeodomain-interacting protein kinase 2 (HIPK2) was identified as a kinase that directly binds and phosphorylates MeCP2 at Ser 80.
• HIPK2-mediated phosphorylation of MeCP2 at Ser 80 was confirmed both in vitro and in vivo.
• MeCP2 cooperates with HIPK2 in inducing apoptosis, with Ser 80 phosphorylation being essential for this process, alongside MeCP2's DNA binding.
• These findings highlight a novel regulatory mechanism for MeCP2 function.

Conclusions:

• HIPK2 is a key kinase that phosphorylates MeCP2 at Ser 80, impacting its function.
• MeCP2 phosphorylation by HIPK2 plays a role in regulating apoptosis and cell growth.
• This study provides the first description of a kinase directly associating with MeCP2 and phosphorylating it in vivo, reinforcing MeCP2's role in cellular regulation.